Acquired resistance to antituberculosis drugs in England, wales, and Northern Ireland, 2000–2015

Miranda G. Loutet*, Jennifer A. Davidson, Tim Brown, Martin Dedicoat, Helen Thomas, Maeve K. Lalor

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Among tuberculosis (TB) patients, acquired resistance to anti-TB drugs represents a failure in the treatment pathway. To improve diagnosis and care for patients with drug-resistant TB, we examined the epidemiology and risk factors associated with acquired drug resistance during 2000–2015 among TB patients in England, Wales, and Northern Ireland. We found acquired resistance in 0.2% (158/67,710) of patients with culture-confirmed TB. Using multivariate logistic regression, we identified the following factors associated with acquired drug resistance: having pulmonary disease; initial resistance to isoniazid, rifampin, or both; a previous TB episode; and being born in China or South Africa. Treatment outcomes were worse for patients with than without acquired resistance. Although acquired resistance is rare in the study area, certain patient groups are at higher risk. Identifying these patients and ensuring that adequate resources are available for treatment may prevent acquisition of resistance, thereby limiting transmission of drug-resistant strains of mycobacteria.

Original languageEnglish
Pages (from-to)524-533
Number of pages10
JournalEmerging Infectious Diseases
Issue number3
Publication statusPublished - Mar 2018

Bibliographical note

Publisher Copyright:
© 2018, Centers for Disease Control and Prevention (CDC). All rights reserved.


Dive into the research topics of 'Acquired resistance to antituberculosis drugs in England, wales, and Northern Ireland, 2000–2015'. Together they form a unique fingerprint.

Cite this